Panacea Life Sciences Holdings, Inc. cash flow statement PLSH

Annual Quarterly

In Q1 of fiscal 2024, the quarter ended Mar 31, 2024, Panacea Life Sciences Holdings, Inc. used $357,090 of cash from operations, down 13.8% from the same quarter a year earlier. It spent $5,000 on capital expenditures. Free cash flow was negative, at -$362,090.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Mar 31, 2024	Q1 FY2024 Mar 31, 2024	Q4 FY2023 Dec 31, 2023	Q3 FY2023 Sep 30, 2023	Q2 FY2023 Jun 30, 2023	Q1 FY2023 Mar 31, 2023	Q4 FY2022 Dec 31, 2022	Q3 FY2022 Sep 30, 2022	Q2 FY2022 Jun 30, 2022
Operating
Depreciation and amortization	2 -0.6%	0 -9.2%	0 +3.3%	0 +0.6%	0 +3.1%	0 +3.4%	0 +8.6%	0 +7.4%	0 -11.0%
Operating cash flow	-2 +31.2%	-0 -13.8%	0 +100.3%	-1 -2.5%	-0 +33.7%	-0 +28.0%	-1 +57.5%	-1 +5.5%	-1 +36.3%
Investing
Capital expenditures	0 -77.9%	0 -67.1%	0	—	0 +18.7%	0 +56.5%	—	0 -30.2%	0
Investing cash flow	-0 +72.8%	-0 +67.1%	-0 +81.9%	-0 +82.1%	-0 -124.0%	-0 -56.5%	-0 -1145.8%	-0 -152.2%	0 -89.1%
Financing
Financing cash flow	2 -33.6%	0 -6.7%	0 -80.4%	1 -11.2%	0 -36.3%	0 -18.0%	1 -51.7%	1 +113.8%	1 -18.4%
Change in cash
Net change in cash	0 +99.7%	0 -89.9%	0 +433.2%	-0 -2655.3%	-0 -234.1%	0 +83.0%	-0 -665.8%	0 +100.2%	-0 -142.0%
Free cash flow	-2 +35.8%	-0 -10.0%	-0	—	-0 +33.2%	-0 +26.2%	—	-1 +10.1%	-1
Per share
Free cash flow per share	—	-0.02	-0.00	—	-0.03	—	—	—	—
Ratios
Free cash flow margin	-58.71%	-34.27%	-8.13%	—	-123.44%	-48.57%	—	-227.03%	-157.06%
Capital expenditures to revenue	1.99%	0.47%	8.29%	—	2.34%	2.25%	—	32.87%	1.68%

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry: Medicinal Chemicals & Botanical Products (SIC 2833)
Listed as: PLSH (OTC)
Fiscal year ends: December 31
Incorporated in: NV
Headquarters: Greenwood Village, CO
SEC filer status: , Emerging growth company
SEC CIK: 1552189
Former names: Exactus, Inc. (until Oct 26, 2021); Spiral Energy Tech., Inc. (until Mar 4, 2016); Solid Solar Energy, Inc. (until Aug 7, 2013)

Other Medicinal Chemicals & Botanical Products companies

All 43 Medicinal Chemicals & Botanical Products companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.